Sie suchten nach: demonstrated greater likelihood (Englisch - Maltesisch)

a greater likelihood of finding cheaper offers
probabilità ikbar li wieħed isib offerti orħos

there is also a greater likelihood of misuse of the voting rights by intermediaries.
hemm ukoll probabbiltà akbar ta’ abbuż tad-drittijiet tal-vot mill-intermedjarji.

both nivolumab-containing arms demonstrated greater objective response rates than ipilimumab regardless of pd-l1 expression levels.
iż-żewġ fergħat li fihom nivolumab urew rati ta’ rispons oġġettiv ikbar minn ta’ ipilimumab irrispettivament mil-livelli ta’ espressjoni ta’ pd-l1.

the involvement of stakeholders is essential because it leads to commitment to the measures and ensure a greater likelihood of compliance of the adopted measures.
l-involviment tal-partijiet interessati huwa essenzjali peress li jwassal għal impenn lejn il-miżuri u jiżgura probabbiltà akbar ta’ konformità mal-miżuri adottati.

ranexa demonstrated greater efficacy than placebo in prolonging exercise time at trough at 12 weeks for both doses studied when used as an add-on therapy.
ranexa wriet effikaċja akbar minn plaċebo fit-titwil taż-żmien ta’ eżerċizzju f’livelli minimi, f’ġimgħa 12 għaż-żewġ dożi studjati meta wżata bħala terapija add-on.

the combination of saxagliptin and dapagliflozin added to metformin consistently demonstrated greater reductions in hba1c irrespective of baseline hba1c compared with saxagliptin or dapagliflozin alone added to metformin.
il- kombinament ta' saxagliptin u dapagliflozin miżjuda ma' metformin wera b'mod konsistenti tnaqqis akbar ta' hba1c irrispettivament mil-linja bażi ta' hba1c meta mqabbel ma saxagliptin jew dapagliflozin miżjuda waħedhom ma' metformin.

if we fail to act, we risk creating a vicious circle where lack of opportunity leads to poor results in school and a greater likelihood of unemployment and poverty."
jekk ma nagħmlu xejn, nirriskjaw li jinħoloq ċirku vizzjuż fejn in-nuqqas ta’ opportunitajiet iwassal għal riżultati baxxi fl-iskola u probabbiltà akbar ta’ qgħad u faqar."

patients with tumour pd-l1 expression by all predefined expression levels in the opdivo group demonstrated greater likelihood of improved survival compared to docetaxel, whereas survival was similar to docetaxel in patients with low or no tumour pd-l1 expression.
il-pazjenti b’espressjoni pd-l1 tat-tumur mil-livelli kollha tal-espressjoni definiti minn qabel fil- grupp opdivo urew probabilità akbar ta’ sopravivenza mtejba meta mqabbla ma’ docetaxel, mentri s-sopravivenza f’pazjenti b’espressjoni pd-l1 tat-tumur baxxa jew mingħajra kienet simili għal docetaxel.

there is much to be gained from using the ppp formula: better cost control (construction and operating costs) and a greater likelihood that the work will be completed to deadline.
il-vantaġġi ta' ppp huma diversi: kontroll aħjar fuq l-ispejjeż (kostruzzjoni u sfruttar) u rata ogħla ta' tlestija tax-xogħolijiet fil-limiti taż-żmien stipulati.

yentreve and pelvic floor muscle training (pfmt): during a 12-week blinded, randomised, controlled study, yentreve demonstrated greater reductions in ief compared with either placebo treatment or with pfmt alone.
yentreve u taħriġ tal-muskolu tal-qiegħ tal-pelvis (pfmt): waqt studju kkontrollat, blinded, randomised, ta' 12-il ġimgħa, yentreve wera tnaqqis akbar fl-ief meta mqabbel jew ma' kura bil- plaċebo jew ma' pfmt waħdu.

duloxetine boehringer ingelheim and pelvic floor muscle training (pfmt): during a 12- week blinded, randomised, controlled study, duloxetine boehringer ingelheim demonstrated greater reductions in ief compared with either placebo treatment or with pfmt alone.
duloxetine boehringer ingelheim u taħriġ tal- muskolu tal- qiegħ tal- pelvis (pfmt): waqt studju kkontrollat, blinded, randomised, ta '12- il ġimgħa, duloxetine boehringer ingelheim wera tnaqqis akbar fl- ief meta mqabbel jew ma' kura bil- plaċebo jew ma 'pfmt waħdu.

in clinical studies of non-liposomal irinotecan administered on a weekly dosage schedule, patients with modestly elevated baseline serum total bilirubin levels (1.0 to 2.0 mg/dl) had a significantly greater likelihood of experiencing first cycle grade 3 or grade 4 neutropenia than those with bilirubin levels that were less than 1.0 mg/dl.
fi studji kliniċi dwar irinotecan mhux lipożomali mogħti fuq skeda ta’ dożaġġ kull ġimgħa, pazjenti b'livelli ta’ bilirubina totali fis-serum modestament għoljin fil-linja bażi (1.0 sa 2.0 mg/dl) kellhom probabbiltà akbar b'mod sinifikanti li jkollhom newtropenija fl-ewwel ċiklu ta’ grad 3 jew grad 4 milli dawk b'livelli ta’ bilirubina li kienu inqas minn 1.0 mg/dl.